Zinc May Reverse Pulmonary Fibrosis
Zinc, a common mineral, may reverse lung damage and improve survival for patients with idiopathic pulmonary fibrosis (IPF), according to researchers from the Women’s Guild Lung Institute at Cedars-Sinai.
Zinc, a common mineral, may reverse lung damage and improve survival for patients with idiopathic pulmonary fibrosis (IPF), according to researchers from the Women’s Guild Lung Institute at Cedars-Sinai.
Research shows it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.
The first of the Purdue team’s novel targeted molecules is designed to slow fibrosis and extend life. The second IPF therapy suppresses fibrosis-inducing cytokine production.
Stem cells collected from human amniotic membrane (one of the two fetal membranes forming the amniotic sac) can slow the progression of scarring in pulmonary fibrosis.
Read MoreAn agreement with Yale gives Veracyte rights to a 52-gene signature developed for predicting disease progression in idiopathic pulmonary fibrosis patients.
Read MoreResearchers have elucidated the novel disease processes involved in the development of pulmonary fibrosis, according to a study published in Nature Communications.
Read MoreThe Pulmonary Fibrosis Foundation’s recent PFF Summit has announced winners for its poster sessions.
Read MorePulmonary fibrosis (PF) is a complex interstitial lung disease that afflicts an estimated 100,000 Americans, with 30-40,000 new cases diagnosed each year.
Read MoreAccording to research in The Lancet Respiratory Medicine, investigational antibody pamrevlumab reduced lung function decline and slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).
Read MoreThe PF Foundation has launched a new PF Drug Development Pipeline tool to help the pulmonary fibrosis community search for different treatment options.
Read MorePulmonary fibrosis drugs pirfenidone and nintedanib appear to increase longevity and decrease hospitalizations in IPF patients.
Read MoreMore than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of...
Read MoreTo date, 23 studies, including abstracts and manuscripts, have been developed or are underway using data from the Pulmonary Fibrosis Foundation Patient Registry.
Read MoreA clinical study of patients with idiopathic pulmonary fibrosis treated with PRM-151 demonstrated the drug had a sustained benefit on 6-minute walking distance and on reducing FVC decline.
Read MoreRespivant Sciences has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
Read More